Celgene partners with Bluebird to develop gene therapies for cancer

03/22/2013 | Genetic Engineering & Biotechnology News

Celgene and Bluebird Bio agreed to collaborate in the discovery, development and marketing of gene therapies for cancer. The collaboration will center on modification of patients' chimeric antigen receptor T cells to target and kill cancer cells. Celgene will pay Bluebird an undisclosed upfront fee and as much as $225 million in option and milestone payments for each product arising from the collaboration.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX